Convalescent Plasma Therapy Market Report 2026

Convalescent Plasma Therapy Market Overview

• Convalescent Plasma Therapy market size has reached to $0.06 billion in 2025 • Expected to grow to $0.11 billion in 2030 at a compound annual growth rate (CAGR) of 13.5% • Growth Driver: Rising Prevalence Of Infectious Diseases Driving The Market Growth Due To Increased Infections • Market Trend: Kamada Ltd. Advances Hyperimmune Globulin Therapy with CYTOGAM for High-Risk Transplant Patients • North America was the largest region in 2025 and Western Europe is the fastest growing region.

What Is Covered Under Convalescent Plasma Therapy Market?

Convalescent plasma is plasma that has been collected from people who have recovered or are convalescing and contains antibodies against the infection-causing microorganism. It is used for the treatment of patients infected by the respective pathogen. The main antibody types of convalescent plasma therapy are IgM, IgG, and IgA. Immunoglobulin A (IgA) is an antibody that is essential for mucous membrane immunological activity. The different applications include prophylaxis, and treatment and are used in various sectors such as hospitals and clinics, laboratories, and research institutes.

What Is The Convalescent Plasma Therapy Market Growth Forecast?

The convalescent plasma therapy market size is expected to see rapid growth in the next few years. It will grow to $0.11 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to preparedness for future outbreaks, advancements in antibody testing, improved plasma storage technologies, expansion of transfusion services, research into immune therapies. Major trends in the forecast period include increased use in emerging infectious disease treatment, growing focus on high-titer antibody plasma, expansion of plasma collection infrastructure, improved donor screening and selection, integration with hospital-based critical care.

Global Convalescent Plasma Therapy Market Segmentation

1) By Antibody type: IgM, IgG, IgA 2) By Application: Prophylaxis, Treatment 3) By End-Users: Hospitals And Clinics, Laboratories And Research institutes Subsegments: 1) By IgM: Early-Stage Infection Plasma, Acute Phase Plasma 2) By IgG: High Titer IgG Plasma, Standard IgG Plasma 3) By IgA: Plasma Rich In IgA, Specific IgA Antibody Plasma

What Are The Drivers Of The Convalescent Plasma Therapy Market?

The rising prevalence of infectious diseases is expected to propel the growth of the convalescent plasma therapy market going forward. Infectious diseases refer to illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can be transmitted from one person to another or through contaminated environments. The prevalence of infectious diseases is rising due to increased urbanization and global travel, which lead to closer human contact and faster spread of pathogens. Convalescent plasma therapy helps combat infectious diseases by using plasma from recovered patients, which contains antibodies that can neutralize pathogens and provide passive immunity to those currently infected, thereby supporting the body’s defense against the disease. For instance, in October 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, an increase from 7.5 million in 2022, representing the highest number recorded since global TB surveillance started. Therefore, the rising prevalence of infectious diseases is driving the growth of the Convalescent Plasma Therapy industry. The increase in the number of hospitals is expected to propel the growth of the convalescent plasma therapy market going forward. A hospital is a specialized medical facility designed to provide a wide range of healthcare services, including diagnosis, treatment, and care for patients with various medical conditions and illnesses. Increased hospital numbers often correlate with improved healthcare infrastructure. This, in turn, translates to better facilities for collecting, processing and administering convalescent plasma, thereby raising the quality of care. For instance, in April 2025, according to the Hellenic Statistical Authority, a Greece-based national government statistics agency, the number of hospitals in the country increased from 265 units in 2022 to 266 units in 2023, reflecting a 0.4% rise. Therefore, the increase in the number of hospitals is driving the growth of the convalescent plasma therapy industry.

Key Players In The Global Convalescent Plasma Therapy Market

Major companies operating in the convalescent plasma therapy market are Bio Farma, Biotest AG, BPL Ltd., LFB SA, Octapharma AG, CSL Behring LLC, Takeda Pharmaceutical Company Ltd., Orthosera Kft., ADMA Biologics Inc., GC Biopharma Corp, Grifols S.A, Sanquin Plasma Products B.V., America's Blood Centers, Blood Centers of America Inc., New York Blood Center, Blood Systems Inc., OneBlood Inc., Gulf Coast Regional Blood Center, Bloodworks Northwest, Blood Assurance Inc., Honolulu Blood-Plasma Bank, Community Blood Center, LifeStream Blood Bank, Kedrion Biopharma Inc.

Global Convalescent Plasma Therapy Market Trends and Insights

Major companies operating in the convalescent plasma therapy market are focusing on developing innovative solutions, such as hyperimmune globulin therapies, to enhance treatment efficacy and address challenges associated with standard plasma therapies. Hyperimmune Globulin Therapies refer to treatments that utilize plasma with a high concentration of specific antibodies, derived from individuals who have recovered from an infection, to provide targeted and potent immune support for patients. For instance, in October 2023, Kamada Ltd., an Israel-based biopharmaceutical company, announced significant advancements regarding its product CYTOGAM (Cytomegalovirus Immune Globulin Intravenous [Human]), now commercially available in the U.S. following FDA approval for its manufacturing facility in Israel. At IDWeek 2023, new clinical data demonstrated a five-year survival benefit for high-risk CMV mismatch lung transplant patients receiving CYTOGAM. Additionally, Kamada has formed its first Scientific Advisory Board to enhance U.S. clinical programs for the product.

Regional Outlook

North America was the largest region in the convalescent plasma therapy market in 2025. Western Europe was the second largest region in the convalescent plasma therapy market. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Convalescent Plasma Therapy Market?

The convalescent plasma therapy market includes revenue earned by IgD and IgE. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Convalescent Plasma Therapy Market Report 2026?

The convalescent plasma therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the convalescent plasma therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.